ABG Sundal Collier acted as sole global coordinator and bookrunner in connection with the SEK 20 million directed share issue in Ascelia Pharma AB

On April 23, 2026, Ascelia Pharma AB (the ‘’Company’’) announced the successful completion of a directed issue of approximately 6.7 million shares at a price of SEK 3.00, raising gross proceeds of SEK 20 million. The Company intends to use the net proceeds to strengthen its balance sheet ahead of a pivotal period for the Company, enhance its negotiation position in partnering discussions and to extend the cash runway into 2027, comfortably past the PDUFA date 3 July 2026, when the US Food and Drug Administration (FDA) is expected to render its decision on the New Drug Application (NDA) for Orviglance.